Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001365|
Recruitment Status : Completed
First Posted : December 10, 2002
Last Update Posted : July 13, 2006
This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease.
Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease.
Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
|Condition or disease||Intervention/treatment||Phase|
|Neurodegenerative Disease Parkinson's Disease||Drug: dextromethorphan||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||42 participants|
|Official Title:||NMDA Receptor Antagonist Treatment of Neurodegenerative Disease|
|Study Start Date :||July 1993|
|Study Completion Date :||June 2001|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001365
|United States, Maryland|
|National Institute of Neurological Disorders and Stroke (NINDS)|
|Bethesda, Maryland, United States, 20892|